KQB 198
Alternative Names: KQB-198Latest Information Update: 25 Jul 2024
At a glance
- Originator Kumquat Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 03 Jun 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT06507306)
- 03 Jun 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Monotherapy, Metastatic disease, Late-stage disease) in USA (PO) (NCT06507306)
- 16 Apr 2024 Small molecule therapeutic licensed to Takeda by Kumquat